Toni Seppälä

European guidelines for #Lynchsyndrome by @EHTG_Tweets and @escp_tweets online (part). See the executive summary available @BJSurgery Thank you @GabrielaMoslein @IonutNegoi @AndyLatchford @mev_dv @ProfEmmaCrosbie @neilajryan @CaPP3 @ASampaioSoares bjssjournals.onlinelibrary.wiley.com/doi/full/10.10…

🚨 Big step forward in cancer research! The EU has awarded €13.6M to the international PREDI-LYNCH project to boost early detection of Lynch syndrome-related cancers. Tampere University is proud to be one of the key partners in this important initiative. tuni.fi/en/news/eu13-6…

New trial coming up - PROSPERITY trial comparing protective ileostomy versus colostomy in anterior rectal resection. Presented at @escp_tweets. Protocol now out in @BMJ_Open! Trial is open for new centers also! Contact @LauraKoskenvuo if interested! bmjopen.bmj.com/content/bmjope…

12/ 🌍 Massive credit to the PLSD team: @k_zalevskaja @PLSDatabase 🧪 25 countries 📈 8000+ carriers 🧠 Prospectively stratified by gene & surgery 📢 This data should guide the next round of guideline updates. 🧵/end 🔗 Read the paper @BJSurgery academic.oup.com/bjs/article/11…

11/ 📣 For clinicians: If LS is confirmed pre-op, discuss: ✅ Risk of metachronous CRC ✅ Surveillance burden ✅ Surgical complications ✅ Functional outcomes 🧬 This is precision surgery — based on real risk.

🧵1/ 🚨 Just out: the PLSD's biggest prospective study yet on Lynch syndrome & colorectal cancer (CRC) surgery. What’s the real risk of a second CRC—and can surgery prevent it? Spoiler: Prior CRC = higher risk. Extended surgery = game changer. 👇 🔗 doi.org/10.1093/bjs/zn…

Tutkimusryhmämme rekrytoi *projektipäällikköä* ohjaamaan kliinisiä ja translationaalisia monikeskustutkimuksia. Hae mukaan tiimiin! tuni.rekrytointi.com/paikat/index.p…

@Aiims1742 @JAMANetworkOpen @cityofhope What was the ctDNA assay used in this study? @MustafaRaoofMD

New paper in @JAMANetworkOpen from @cityofhope calls into the question the utility of serial tumor informed ctDNA measurement versus routine imaging based surveillance for recurrence following curative intent surgery for #ColorectalCancer. Only 1.6% of patients who underwent serial ctDNA monitoring for recurrence were actually disease free following metastatecomy at the time of cutoff. Each patient underwent ctDNA measurement every three months for 1st two years following surgery, and then every six months for next three years.

Excited to share our urine tumor DNA assay #UroScout results published today in @EUplatinum 👉 authors.elsevier.com/c/1jzvn14kplyz… Sensitive Detection of Urothelial Cancer via High-volume Urine DNA Analysis 🧬 497 urine DNA samples from 281 patients ✅100% sens for ≥T1 bladder cancer ✅ 94% sens for Ta bladder cancer ✅ 92% sens for any grade UTUC ✅ 100% sens for MI/HG-UTUC ✅ 90% sens for recurrence detection ✅ Identification of Lynch syndrome 💡 Three-tier diagnostic workflow for cystoscopy pre-screening 👉 Potential to replace ~80% of diagnostic cystoscopies 👉 2 utDNA mutations, AF≥5% ➡️ PPV 100% ➡️ 69% of UC patients could be scheduled directly for OR procedures @TampereUni @Tays_sairaala @VanProstateCtr #MattiAnnala @TVeitonmaki @NykterLab @ResearchWyatt @pcvblack @G_Vandekerkhove @D_C_Muller 🔍 Check supplementaries for more results Link: authors.elsevier.com/c/1jzvn14kplyz…

presentation of our upcoming PROSPERITY trial at #escp2024 by @LauraKoskenvuo @villesallinen @Adductor

New @TheLancet - Adam et al - Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet trial) thelancet.com/journals/lance… #CRCSM #LiverTwitter

MSc @SievanenTero defended his PhD thesis today @JYUsport_health on ”The associations of circulating microRNAs and lifestyle habits with cancer risk in #Lynchsyndrome ”. The honorable opponent Arto Mannermaa @UniEastFinland, kustos @eija_laakkonen @gerec_fi #Y-EHTG